Bioniz Therapeutics Inc

bioniz therapeutics is a private biopharmaceutical company leading the discovery and development of first-in-class anti-cytokine therapies to treat cancer and autoimmune diseases driven by unregulated t-cell biology. bioniz leverages its world class expertise in cytokine biology to develop a pipeline of novel peptide therapeutics to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact. the company’s lead product candidate, bnz-1, has successfully completed a phase 1/2 clinical trial in refractory cutaneous t-cell lymphoma (rctcl). bioniz is also evaluating bnz-1 for the treatment of autoimmune diseases, including alopecia areata and vitiligo. bnz-2 and bnz-3 are being developed as potential treatments for celiac disease and inflammatory bowel disease.